Literature DB >> 2149957

Hematologic disorders in 13 patients with acquired trisomy 21 and 13 individuals with Down syndrome.

G W Dewald1, J L Diez-Martin, S L Steffen, R B Jenkins, P J Stupca, E O Burgert.   

Abstract

To study the role of trisomy 21 in hematologic malignancies, we investigated the hematologic disorders of 13 patients with acquired trisomy 21 and 13 individuals with Down syndrome (DS). The most common hematologic malignancy among the patients with acquired trisomy 21 involved both granulocytic and monocytic lineages. By comparison, the hematologic disorders among the DS patients were predominantly acute lymphocytic leukemia and acute megakaryocytic leukemia. Although our sample was small, our results suggest that most patients with acquired trisomy 21 have different hematologic disorders than individuals with DS. Perhaps the role of trisomy 21 in the development of hematologic malignancy is different in constitutional trisomy 21 than it is in acquired trisomy 21.

Entities:  

Mesh:

Year:  1990        PMID: 2149957     DOI: 10.1002/ajmg.1320370750

Source DB:  PubMed          Journal:  Am J Med Genet Suppl        ISSN: 1040-3787


  4 in total

1.  CD19-positive acute myeloblastic leukemia with trisomy 21 as a sole acquired karyotypic abnormality.

Authors:  Hua-feng Wang; Yi-zhi Cheng; Huan-ping Wang; Zhi-mei Chen; Ji-yu Lou; Jie Jin
Journal:  J Zhejiang Univ Sci B       Date:  2009-11       Impact factor: 3.066

2.  Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field.

Authors:  M E Coussons-Read; L S Crnic
Journal:  Behav Genet       Date:  1996-01       Impact factor: 2.805

3.  Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.

Authors:  Paolo Strati; Naval Daver; Farhad Ravandi; Naveen Pemmaraju; Sherry Pierce; Guillermo Garcia-Manero; Aziz Nazha; Tapan Kadia; Elias Jabbour; Gautam Borthakur; Stefan Faderl; Alfonso Quintas-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-08-19

4.  Thyroid function and plasma immunoglobulins in subjects with Down's syndrome (DS) during ontogenesis and zinc therapy.

Authors:  M Sustrová; V Strbák
Journal:  J Endocrinol Invest       Date:  1994-06       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.